Tacrolimus: Difference between revisions
(serious effects) |
(common effects) |
||
| Line 85: | Line 85: | ||
===Common=== | ===Common=== | ||
*tremor | |||
*diarrhea | |||
*headache | |||
*HTN | |||
*Cr incr. | |||
*infection | |||
*nausea/vomiting | |||
*insomnia | |||
*pain | |||
*hypophosphatemia | |||
*constipation | |||
*asthenia | |||
*edema, peripheral | |||
*hypomagnesemia | |||
*fever | |||
*anemia | |||
*diabetes mellitus/hyperglycemia | |||
*paresthesia | |||
*LFTs elevated | |||
*hyperlipidemia | |||
*hyperkalemia | |||
*anorexia | |||
*dyspepsia | |||
*arthralgia | |||
*dyspnea | |||
*pruritus/rash | |||
*hypokalemia | |||
*dizziness | |||
*cough | |||
*leukopenia | |||
*photosensitivity | |||
*bronchitis | |||
==Pharmacology== | ==Pharmacology== | ||
Revision as of 03:30, 9 February 2016
Administration
- Type: immunosuppressant
- Dosage Forms: 0.5,1,5
- Routes of Administration: PO, topical, IV
- Common Trade Names:Prograf
Adult Dosing
Heart transplant rejection prophylaxis
- 0.075 mg/kg/day PO divided q12h
- Start: >6h post-transplant; Info: adjust dose based on serum levels
Liver transplant rejection prophylaxis
- 0.1-0.15 mg/kg/day PO divided q12h
- Start: >6h post-transplant; Info: adjust dose based on serum levels
Kidney transplant rejection prophylaxis
- 0.1-0.2 mg/kg/day PO divided q12h
- Start: w/in 24h post-transplant; delay if renal fxn not adequate; Info: adjust dose based on serum levels
Pediatric Dosing
Liver transplant rejection prophylaxis
- 0.15-0.2 mg/kg/day PO divided q12h
- Start: >6h post-transplant; Info: adjust dose based on serum levels
Special Populations
- Pregnancy Rating: Pregnancy Category C
- Lactation risk: possibly unsafe
Renal Dosing
- Adult:
- kidney transplant: give lowest recommended dose, may consider further dose decr.; postop oliguria: start 6-24h post-transplant; may delay until renal fxn adequate; HD: not defined
- all other transplants: give lowest recommended dose, may consider further dose decr.; HD: not defined
- Pediatric: give lowest recommended dose, may consider further dose decr.; HD: not defined
Hepatic Dosing
- Adult: give lowest recommended dose, may consider further dose decr.; Child-Pugh Score >10: decr. dose, amount not defined
- Pediatric: give lowest recommended dose, may consider further dose decr.; Child-Pugh Score >10: decr. dose, amount not defined
Contraindications
- Allergy to class/drug
- hypersensitivity to castor oil derivatives (IV form)
- liver transplant use (ER cap form)
- electrolyte abnormalities, uncorrected
- congenital long QT syndrome
- caution if QT prolongation
- caution if QT prolongation family hx
- caution if torsades de pointes hx
- caution if ventricular arrhythmias
- caution if bradycardia
- caution if recent MI
- caution if CHF
- caution in female pts
- caution in black pts
- caution in Hispanic pts
- caution if renal impairment
- caution if hepatic impairment
Adverse Reactions
Serious
- immunosuppression
- malignancy
- lymphoma
- post-transplant lymphoproliferative disorder
- infection, severe
- CMV
- PML
- BK virus-assoc. nephropathy
- Stevens-Johnson syndrome
- toxic epidermal necrolysis
- anaphylaxis
- nephrotoxicity
- neurotoxicity
- posterior reversible encephalopathy syndrome
- seizures
- myocardial hypertrophy
- pericardial effusion
- QT prolongation
- torsades de pointes
- hyperkalemia, severe
- HTN, severe
- diabetes mellitus
- myelosuppression
- DIC
- thrombocytopenic purpura
- hemolytic anemia
- pure red cell aplasia
Common
- tremor
- diarrhea
- headache
- HTN
- Cr incr.
- infection
- nausea/vomiting
- insomnia
- pain
- hypophosphatemia
- constipation
- asthenia
- edema, peripheral
- hypomagnesemia
- fever
- anemia
- diabetes mellitus/hyperglycemia
- paresthesia
- LFTs elevated
- hyperlipidemia
- hyperkalemia
- anorexia
- dyspepsia
- arthralgia
- dyspnea
- pruritus/rash
- hypokalemia
- dizziness
- cough
- leukopenia
- photosensitivity
- bronchitis
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
